Download PDF
1 / Pages

Other users also viewed these articles

The Janus of a disease: Diabetes and metabolic dysfunction-associated fatty liver disease Francisco Barrera; Javier Uribe; Nixa Olvares; Paula Huerta; Daniel Cabrera; Manuel Romero-Gómez;
Ann Hepatol. 2024;29:
Body weight loss and glycemic control on the outcomes of patients with NAFLD. The role of new antidiabetic agents Diego García-Compeán; Ramesh Kumar; Ángel Noe del Cueto-Aguilera; Héctor Jesús Maldonado-Garza; Jesús Zacarías Villarreal-Pérez;
Ann Hepatol. 2023;28:
Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study Samantha Thifani Alrutz Barcelos; Amanda Souza Silva-Sperb; Helena Abadie Moraes; Larisse Longo; Bruna Concheski de Moura; Matheus Truccolo Michalczuk; Carolina Uribe-Cruz; Carlos Thadeu Schmidt Cerski; Themis Reverbel da Silveira; Valesca Dall'Alba; Mário Reis Álvares-da-Silva;
Ann Hepatol. 2023;28: